Shares of Clovis Oncology Inc (NASDAQ:CLVS) ended Wednesday session in green amid volatile trading. The shares closed up +0.64 points or 2.70% at $24.35 with 1.02 million shares getting traded. Post opening the session at $23.75, the shares hit an intraday low of $23.65 and an intraday high of $24.35 and the price vacillated in this range throughout the day. The company has a market cap of $949.92 million and the numbers of outstanding shares have been calculated to be 38.50 million shares.
Clovis Oncology Inc (CLVS) on August 23, 2016 announced that the U.S. Food and Drug Administration (FDA) has accepted Clovis’ New Drug Application (NDA) for accelerated approval of rucaparib and granted priority review status to the application with a Prescription Drug User Fee Act (PDUFA) date of February 23, 2017. In late June 2016, Clovis completed its NDA submission of rucaparib to the FDA for the treatment of advanced ovarian cancer in patients with deleterious BRCA-mutated tumors inclusive of both germline and somatic BRCA mutations (as detected by an FDA-approved test), and who have been treated with two or more chemotherapies. Rucaparib was granted Breakthrough Therapy Designation for the proposed indication by the FDA in April 2015.
“The acceptance of the rucaparib NDA submission represents an important milestone for rucaparib, and for Clovis,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “There is tremendous need for additional therapeutic options for patients with advanced mutant BRCA ovarian cancer and we look forward to cooperating with FDA on the rucaparib NDA review.”
Shares of Eli Lilly and Co (NYSE:LLY) ended Wednesday session in green amid volatile trading. The shares closed up +0.08 points or 0.10% at $78.59 with 2.97 million shares getting traded. Post opening the session at $78.49, the shares hit an intraday low of $78.26 and an intraday high of $78.89 and the price vacillated in this range throughout the day. The company has a market cap of $88.62 billion and the numbers of outstanding shares have been calculated to be 1.10 billion shares.
On Aug. 31, 2016 The board of directors of Eli Lilly and Company (LLY) has elected Jamere Jackson as a new member, effective October 1, 2016. As a member of Lilly’s board, he will serve on the Audit and Finance committees.
Jackson is currently chief financial officer of Nielsen Holdings plc (Nielsen).
“I am delighted to welcome Jamere Jackson to the Lilly board,” said John C. Lechleiter, Ph.D., chairman, president and chief executive officer. “Jamere brings a wealth of global financial experience, including a strong background in strategic planning. His experience at Nielsen will also provide an important perspective to our business and help broaden our understanding of consumer markets and strategies.”
Prior to joining Nielsen in 2014, Jackson was with General Electric (GE). His last position there was vice president and chief financial officer for GE Oil & Gas, drilling and surface division. In that role, he was responsible for driving financial rigor, developing strategy and implementing change across the drilling and surface portfolio.